enhertu
daiichi sankyo brasil farmacÊutica ltda - trastuzumabe deruxtecana - antineoplasico
abevmy
mylan laboratorios ltda - bevacizumabe - antineoplasico
epysqli
samsung bioepis nl b.v. - eculizumab - hemoglobinúria, paroxística - imunossupressores - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
phesgo
roche registration gmbh - pertuzumab, trastuzumab - neoplasias do peito - agentes antineoplásicos - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
keytruda
organon farmacÊutica ltda. - pembrolizumabe - outros antineoplasicos
ipique
rotterdam biologics b.v. - bevacizumab - degeneração macular úmida - oftalmológicos - treatment of neovascular (wet) age-related macular degeneration (amd).
ontruzant
samsung bioepis br pharmaceutical ltda. - trastuzumabe - antineoplasico
perjeta her
produtos roche quÍmicos e farmacÊuticos s.a. - pertuzumabe, trastuzumabe - antineoplasico
phesgo
produtos roche quÍmicos e farmacÊuticos s.a. - pertuzumabe, trastuzumabe - antineoplasico
amelivu
samsung bioepis br pharmaceutical ltda. - ranibizumabe - outros medicamentos com acao no aparelho visual